Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2016

Open Access 01-12-2016 | Review

Role of prophylactic central compartment lymph node dissection in clinically N0 differentiated thyroid cancer patients: analysis of risk factors and review of modern trends

Authors: Giovanni Conzo, Ernesto Tartaglia, Nicola Avenia, Pier Giorgio Calò, Annamaria de Bellis, Katherine Esposito, Claudio Gambardella, Sergio Iorio, Daniela Pasquali, Luigi Santini, Maria Antonia Sinisi, Antonio Agostino Sinisi, Mario Testini, Andrea Polistena, Giuseppe Bellastella

Published in: World Journal of Surgical Oncology | Issue 1/2016

Login to get access

Abstract

In the last years, especially thanks to a large diffusion of ultrasound-guided FNBs, a surprising increased incidence of differentiated thyroid cancer (DTC), “small” tumors and microcarcinomas have been reported in the international series. This led endocrinologists and surgeons to search for “tailored” and “less aggressive” therapeutic protocols avoiding risky morbidity and useless “overtreatment”. Considering the most recent guidelines of referral endocrine societies, we analyzed the role of routine or so-called prophylactic central compartment lymph node dissection (RCLD), also considering its benefits and risks. Literature data showed that the debate is still open and the surgeons are divided between proponents and opponents of its use. Even if lymph node metastases are commonly observed, and in up to 90 % of DTC cases micrometastases are reported, the impact of lymphatic involvement on long-term survival is subject to intensive research and the best indications of lymph node dissection are still controversial. Identification of prognostic factors for central compartment metastases could assist surgeons in determining whether to perform RLCD. Considering available evidence, a general agreement to definitely reserve RCLD to “high-risk” cases was observed. More clinical researches, in order to identify risk factors of meaningful predictive power and prospective long-term randomized trials, should be useful to validate this selective approach.
Literature
1.
go back to reference Agate L, Lorusso L, Elisei R. New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. J Endocrinol Invest. 2012;35:3–9.PubMed Agate L, Lorusso L, Elisei R. New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. J Endocrinol Invest. 2012;35:3–9.PubMed
2.
go back to reference Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–7.CrossRefPubMed Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–7.CrossRefPubMed
3.
go back to reference Wang Y, Wang W. Increasing Incidence of Thyroid Cancer in Shanghai, China, 1983–2007. Asia Pac J Public Health. 2015;27(2):NP223–9.CrossRefPubMed Wang Y, Wang W. Increasing Incidence of Thyroid Cancer in Shanghai, China, 1983–2007. Asia Pac J Public Health. 2015;27(2):NP223–9.CrossRefPubMed
4.
go back to reference Bellevicine C, Vigliar E, Malapelle U, Pisapia P, Conzo G, Biondi B, et al. Cytopathologists can reliably perform ultrasound-guided thyroid fine needle aspiration: a 1-year audit on 3715 consecutive cases. Cytopathology. 2015;21 [Epub ahead of print]. Bellevicine C, Vigliar E, Malapelle U, Pisapia P, Conzo G, Biondi B, et al. Cytopathologists can reliably perform ultrasound-guided thyroid fine needle aspiration: a 1-year audit on 3715 consecutive cases. Cytopathology. 2015;21 [Epub ahead of print].
5.
go back to reference Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.CrossRefPubMedPubMedCentral Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.CrossRefPubMedPubMedCentral
6.
go back to reference Conzo G, Circelli L, Pasquali D, Sinisi A, Sabatino L, Accardo G, et al. Lessons to be learned from the clinical management of a MEN 2A patient bearing a novel 634/640/700 triple mutation of the RET proto-oncogene. Clin Endocrinol. 2012;77(6):934–6.CrossRef Conzo G, Circelli L, Pasquali D, Sinisi A, Sabatino L, Accardo G, et al. Lessons to be learned from the clinical management of a MEN 2A patient bearing a novel 634/640/700 triple mutation of the RET proto-oncogene. Clin Endocrinol. 2012;77(6):934–6.CrossRef
7.
go back to reference Conzo G, Polistena A, Calò PG, Bononi P, Gambardella C, Mauriello C, Tartaglia E, et al. Efficacy of combined treatment for Anaplastic Thyroid Carcinoma: results of a multinstitutional retrospective analysis. Int J Surg. 2014;12 Suppl 1:S178–82.CrossRefPubMed Conzo G, Polistena A, Calò PG, Bononi P, Gambardella C, Mauriello C, Tartaglia E, et al. Efficacy of combined treatment for Anaplastic Thyroid Carcinoma: results of a multinstitutional retrospective analysis. Int J Surg. 2014;12 Suppl 1:S178–82.CrossRefPubMed
8.
go back to reference Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMed Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMed
9.
go back to reference Di Vizio D, Insabato L, Conzo G, Zafonte BT, Ferrara G, Pettinato G. Sarcomatoid carcinoma of the colon: a case report with literature review. Tumori. 2001;87(6):431–5.PubMed Di Vizio D, Insabato L, Conzo G, Zafonte BT, Ferrara G, Pettinato G. Sarcomatoid carcinoma of the colon: a case report with literature review. Tumori. 2001;87(6):431–5.PubMed
10.
go back to reference Troncone G, Volante M, Iaccarino A, Zeppa P, Cozzolino I, Malapelle U, et al. Cyclin D1 and D3 overexpression predicts malignant behavior in thyroid fine-needle aspirates suspicious for Hurtle cell neoplasms. Cancer Cytopathol. 2009;117(6):522–9. Troncone G, Volante M, Iaccarino A, Zeppa P, Cozzolino I, Malapelle U, et al. Cyclin D1 and D3 overexpression predicts malignant behavior in thyroid fine-needle aspirates suspicious for Hurtle cell neoplasms. Cancer Cytopathol. 2009;117(6):522–9.
11.
go back to reference Pasquali D, Santoro A, Bufo P, Conzo G, Deery WJ, Renzullo A, et al. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and braf mutation. Thyroid. 2011;21(4):391–9.CrossRefPubMed Pasquali D, Santoro A, Bufo P, Conzo G, Deery WJ, Renzullo A, et al. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and braf mutation. Thyroid. 2011;21(4):391–9.CrossRefPubMed
12.
go back to reference Kim HJ, Sohn SY, Jang HW, Kim SW, Chung JH. Multifocality, but not bilaterality, is a predictor of disease recurrence/persistence of papillary thyroid carcinoma. World J Surg. 2013;37(2):376–84.CrossRefPubMed Kim HJ, Sohn SY, Jang HW, Kim SW, Chung JH. Multifocality, but not bilaterality, is a predictor of disease recurrence/persistence of papillary thyroid carcinoma. World J Surg. 2013;37(2):376–84.CrossRefPubMed
13.
go back to reference Ito Y, Fukushima M, Higashiyama T, Kihara M, Takamura Y, Kobayashi K, et al. Tumor size is the strongest predictor of microscopic lymph node metastasis and lymph node recurrence of N0 papillary thyroid carcinoma. Endocr J. 2013;60(1):113–7.CrossRefPubMed Ito Y, Fukushima M, Higashiyama T, Kihara M, Takamura Y, Kobayashi K, et al. Tumor size is the strongest predictor of microscopic lymph node metastasis and lymph node recurrence of N0 papillary thyroid carcinoma. Endocr J. 2013;60(1):113–7.CrossRefPubMed
14.
go back to reference Cirocchi R, Boselli C, Guarino S, Sanguinetti A, Trastulli S, Desiderio J, et al. Total thyroidectomy with ultrasonic dissector for cancer: multicentric experience. World J Surg Oncol. 2012;10:70.CrossRefPubMedPubMedCentral Cirocchi R, Boselli C, Guarino S, Sanguinetti A, Trastulli S, Desiderio J, et al. Total thyroidectomy with ultrasonic dissector for cancer: multicentric experience. World J Surg Oncol. 2012;10:70.CrossRefPubMedPubMedCentral
15.
go back to reference Goddard JA, Steward DL. Prophylactic central lymph node dissection in differentiated thyroid cancer. Endocrine. 2013;44(2):275–7.CrossRefPubMed Goddard JA, Steward DL. Prophylactic central lymph node dissection in differentiated thyroid cancer. Endocrine. 2013;44(2):275–7.CrossRefPubMed
16.
go back to reference Conzo G, Pasquali D, Bellastella G, Esposito K, Carella C, De Bellis A, et al. Total thyroidectomy, without prophylactic central lymph node dissection, in the treatment of differentiated thyroid cancer. Clinical retrospective study on 221 cases. Endocrine. 2013;44(2):419–25.CrossRefPubMed Conzo G, Pasquali D, Bellastella G, Esposito K, Carella C, De Bellis A, et al. Total thyroidectomy, without prophylactic central lymph node dissection, in the treatment of differentiated thyroid cancer. Clinical retrospective study on 221 cases. Endocrine. 2013;44(2):419–25.CrossRefPubMed
17.
go back to reference Mazzaferri EL, Doherty GM, Steward DL. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid. 2009;19(7):683–9.CrossRefPubMed Mazzaferri EL, Doherty GM, Steward DL. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid. 2009;19(7):683–9.CrossRefPubMed
18.
go back to reference Conzo G, Avenia N, Bellastella G, Candela G, de Bellis A, Esposito K, et al. The role of surgery in the current management of differentiated thyroid cancer. Endocrine. 2014;47(2):380–8.CrossRefPubMed Conzo G, Avenia N, Bellastella G, Candela G, de Bellis A, Esposito K, et al. The role of surgery in the current management of differentiated thyroid cancer. Endocrine. 2014;47(2):380–8.CrossRefPubMed
19.
go back to reference Conzo G, Calo’ PG, Sinisi AA, De Bellis A, Pasquali D, Iorio S, Tartaglia E, et al. Impact of prophylactic central compartment neck dissection on locoregional recurrence of differentiated thyroid cancer in clinically node-negative patients: a retrospective study of a large clinical series. Surgery. 2014;155(6):998–1005.CrossRefPubMed Conzo G, Calo’ PG, Sinisi AA, De Bellis A, Pasquali D, Iorio S, Tartaglia E, et al. Impact of prophylactic central compartment neck dissection on locoregional recurrence of differentiated thyroid cancer in clinically node-negative patients: a retrospective study of a large clinical series. Surgery. 2014;155(6):998–1005.CrossRefPubMed
20.
go back to reference Viola D, Materazzi G, Valerio L, Molinari E, Agate L, Faviana P, et al. Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. J Clin Endocrinol Metab. 2015;100(4):1316–24.CrossRefPubMed Viola D, Materazzi G, Valerio L, Molinari E, Agate L, Faviana P, et al. Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. J Clin Endocrinol Metab. 2015;100(4):1316–24.CrossRefPubMed
21.
go back to reference Memon A, Godward S, Williams D, Siddique I, Al-Saleh K. Dental x-rays and the risk of thyroid cancer: a case–control study. Acta Oncol. 2010;49(4):447–53.CrossRefPubMed Memon A, Godward S, Williams D, Siddique I, Al-Saleh K. Dental x-rays and the risk of thyroid cancer: a case–control study. Acta Oncol. 2010;49(4):447–53.CrossRefPubMed
22.
go back to reference Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med. 1998;338(11):712–8.CrossRefPubMed Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med. 1998;338(11):712–8.CrossRefPubMed
23.
go back to reference Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2008;93(3):809–14.CrossRefPubMedPubMedCentral Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2008;93(3):809–14.CrossRefPubMedPubMedCentral
26.
go back to reference Bell B, Mazzaferri EL. Familial adenomatous polyposis (Gardner's syndrome) and thyroid carcinoma. A case report and review of the literature. Dig Dis Sci. 1993;38(1):185–90.CrossRefPubMed Bell B, Mazzaferri EL. Familial adenomatous polyposis (Gardner's syndrome) and thyroid carcinoma. A case report and review of the literature. Dig Dis Sci. 1993;38(1):185–90.CrossRefPubMed
27.
go back to reference Steinhagen E, Guillem JG, Chang G, Salo-Mullen EE, Shia J, Fish S, et al. The prevalence of thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis may be higher than previously recognized. Clin Colorectal Cancer. 2012;11(4):304–8.CrossRefPubMed Steinhagen E, Guillem JG, Chang G, Salo-Mullen EE, Shia J, Fish S, et al. The prevalence of thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis may be higher than previously recognized. Clin Colorectal Cancer. 2012;11(4):304–8.CrossRefPubMed
28.
29.
go back to reference Kitahara CM, Platz EA, Freeman LE, Hsing AW, Linet MS, Park Y, et al. Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol Biomarkers Prev. 2011;20(3):464–72.CrossRefPubMedPubMedCentral Kitahara CM, Platz EA, Freeman LE, Hsing AW, Linet MS, Park Y, et al. Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol Biomarkers Prev. 2011;20(3):464–72.CrossRefPubMedPubMedCentral
30.
31.
go back to reference Jung SK, Kim K, Tae K, Kong G, Kim MK. The effect of raw vegetable and fruit intake on thyroid cancer risk among women: a case–control study in South Korea. Br J Nutr. 2013;109(1):118–28.CrossRefPubMed Jung SK, Kim K, Tae K, Kong G, Kim MK. The effect of raw vegetable and fruit intake on thyroid cancer risk among women: a case–control study in South Korea. Br J Nutr. 2013;109(1):118–28.CrossRefPubMed
32.
go back to reference Rezzónico JN, Rezzónico M, Pusiol E, Pitoia F, Niepomniszcze H. Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab Syndr Relat Disord. 2009;7(4):375–80.CrossRefPubMed Rezzónico JN, Rezzónico M, Pusiol E, Pitoia F, Niepomniszcze H. Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab Syndr Relat Disord. 2009;7(4):375–80.CrossRefPubMed
33.
go back to reference Kilfoy BA, Zhang Y, Park Y, Holford TR, Schatzkin A, Hollenbeck A, Ward MH. Dietary nitrate and nitrite and the risk of thyroid cancer in the NIH-AARP Diet and Health Study. Int J Cancer. 2011;129(1):160–72.CrossRefPubMedPubMedCentral Kilfoy BA, Zhang Y, Park Y, Holford TR, Schatzkin A, Hollenbeck A, Ward MH. Dietary nitrate and nitrite and the risk of thyroid cancer in the NIH-AARP Diet and Health Study. Int J Cancer. 2011;129(1):160–72.CrossRefPubMedPubMedCentral
34.
go back to reference Malandrino P, Pellegriti G, Attard M, Violi MA, Giordano C, Sciacca L, et al. Papillary thyroid microcarcinomas: a comparative study of the characteristics and risk factors at presentation in two cancer registries. J Clin Endocrinol Metab. 2013;98(4):1427–34.CrossRefPubMed Malandrino P, Pellegriti G, Attard M, Violi MA, Giordano C, Sciacca L, et al. Papillary thyroid microcarcinomas: a comparative study of the characteristics and risk factors at presentation in two cancer registries. J Clin Endocrinol Metab. 2013;98(4):1427–34.CrossRefPubMed
35.
go back to reference Rosato L, De Toma G, Avenia N. Indicazioni alla linfoadenectomia cervicale nel carcinoma differenziato. Trattato Italiano di Endocrinochirugia: Tiroide, Paratiroide, Surrene e Pancreas Endocrino. Grafica Santhiatese Editrice. 2008;1:245–56. Rosato L, De Toma G, Avenia N. Indicazioni alla linfoadenectomia cervicale nel carcinoma differenziato. Trattato Italiano di Endocrinochirugia: Tiroide, Paratiroide, Surrene e Pancreas Endocrino. Grafica Santhiatese Editrice. 2008;1:245–56.
36.
go back to reference Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid. 1999;9(5):421–7.CrossRefPubMed Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid. 1999;9(5):421–7.CrossRefPubMed
37.
go back to reference Akslen LA, LiVolsi VA. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer. 2000;88(8):1902–8.CrossRefPubMed Akslen LA, LiVolsi VA. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer. 2000;88(8):1902–8.CrossRefPubMed
38.
go back to reference Sugg SL, Zheng L, Rosen IB, Freeman JL, Ezzat S, Asa SL. ret/PTC-1, −2, and −3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential? J Clin Endocrinol Metab. 1996;81(9):3360–5.CrossRefPubMed Sugg SL, Zheng L, Rosen IB, Freeman JL, Ezzat S, Asa SL. ret/PTC-1, −2, and −3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential? J Clin Endocrinol Metab. 1996;81(9):3360–5.CrossRefPubMed
39.
go back to reference Rotstein L. The role of lymphadenectomy in the management of papillary carcinoma of the thyroid. J Surg Oncol. 2009;99(4):186–8.99. 186–8.CrossRefPubMed Rotstein L. The role of lymphadenectomy in the management of papillary carcinoma of the thyroid. J Surg Oncol. 2009;99(4):186–8.99. 186–8.CrossRefPubMed
40.
go back to reference Suman P, Wang CH, Abadin SS, Moo-Young TA, Prinz RA, Winchester DJ. Risk factors for central lymph node metastasis in papillary thyroid carcinoma: a National Cancer Data Base (NCDB) study. Surgery. 2016;159(1):31–40.CrossRefPubMed Suman P, Wang CH, Abadin SS, Moo-Young TA, Prinz RA, Winchester DJ. Risk factors for central lymph node metastasis in papillary thyroid carcinoma: a National Cancer Data Base (NCDB) study. Surgery. 2016;159(1):31–40.CrossRefPubMed
41.
go back to reference So YK, Son YI, Hong SD, Seo MY, Baek CH, Jeong HS, Chung MK. Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections. Surgery. 2010;148(3):526–31.CrossRefPubMed So YK, Son YI, Hong SD, Seo MY, Baek CH, Jeong HS, Chung MK. Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections. Surgery. 2010;148(3):526–31.CrossRefPubMed
42.
go back to reference Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 1996;5(1):43–63.PubMed Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 1996;5(1):43–63.PubMed
43.
go back to reference Londero SC, Krogdahl A, Bastholt L, Overgaard J, Pedersen HB, Hahn CH, et al. Papillary thyroid carcinoma in Denmark, 1996–2008: outcome and evaluation of established prognostic scoring systems in a prospective national cohort. Thyroid. 2015;25(1):78–84.CrossRefPubMed Londero SC, Krogdahl A, Bastholt L, Overgaard J, Pedersen HB, Hahn CH, et al. Papillary thyroid carcinoma in Denmark, 1996–2008: outcome and evaluation of established prognostic scoring systems in a prospective national cohort. Thyroid. 2015;25(1):78–84.CrossRefPubMed
44.
go back to reference Sun W, Lan X, Zhang H, Dong W, Wang Z, He L, et al. Risk Factors for central lymph node metastasis in CN0 papillary thyroid carcinoma: a systematic review and meta-analysis. PLoS One. 2015;10(10):e0139021.CrossRefPubMedPubMedCentral Sun W, Lan X, Zhang H, Dong W, Wang Z, He L, et al. Risk Factors for central lymph node metastasis in CN0 papillary thyroid carcinoma: a systematic review and meta-analysis. PLoS One. 2015;10(10):e0139021.CrossRefPubMedPubMedCentral
45.
go back to reference Hakala TT, Kholová I. Changes in classification of follicular thyroid cancers. Thyroid. 2016. [Epub ahead of print]. Hakala TT, Kholová I. Changes in classification of follicular thyroid cancers. Thyroid. 2016. [Epub ahead of print].​
46.
go back to reference Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, et al. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014;12(12):1671–80.PubMed Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, et al. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014;12(12):1671–80.PubMed
47.
go back to reference Jeong JJ, Lee YS, Lee SC, Kang SW, Chung WY, Chang HS, et al. A scoring system for prediction of lateral neck node metastasis from papillary thyroid cancer. J Korean Med Sci. 2011;26(8):996–1000.CrossRefPubMedPubMedCentral Jeong JJ, Lee YS, Lee SC, Kang SW, Chung WY, Chang HS, et al. A scoring system for prediction of lateral neck node metastasis from papillary thyroid cancer. J Korean Med Sci. 2011;26(8):996–1000.CrossRefPubMedPubMedCentral
48.
go back to reference Lim Y, Choi E, Yoon YH, Kim EH, Koo BS. Central lymph node metastases in unilateral papillary thyroid microcarcinoma. Br J Surg. 2009;96(3):253–7.CrossRefPubMed Lim Y, Choi E, Yoon YH, Kim EH, Koo BS. Central lymph node metastases in unilateral papillary thyroid microcarcinoma. Br J Surg. 2009;96(3):253–7.CrossRefPubMed
49.
go back to reference Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg. 2002;26(1):22–8.CrossRefPubMed Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg. 2002;26(1):22–8.CrossRefPubMed
50.
go back to reference Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.CrossRefPubMed Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.CrossRefPubMed
51.
go back to reference Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 2004;6(4):313–9.CrossRefPubMed Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 2004;6(4):313–9.CrossRefPubMed
52.
go back to reference Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28(7):742–62.CrossRefPubMed Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28(7):742–62.CrossRefPubMed
53.
go back to reference Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90(12):6373–9.CrossRefPubMed Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90(12):6373–9.CrossRefPubMed
54.
go back to reference Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. Association between BRAFV600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493–501.CrossRefPubMedPubMedCentral Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. Association between BRAFV600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493–501.CrossRefPubMedPubMedCentral
55.
go back to reference Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Naþ/I targeting to the membrane. Endocr Relat Cancer. 2006;13(1):257–69.CrossRefPubMed Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Naþ/I targeting to the membrane. Endocr Relat Cancer. 2006;13(1):257–69.CrossRefPubMed
56.
go back to reference Hod R, Bachar G, Sternov Y, Shvero J. Insular thyroid carcinoma: a retrospective clinicopathologic study. Am J Otolaryngol. 2013;34(4):292–5.CrossRefPubMed Hod R, Bachar G, Sternov Y, Shvero J. Insular thyroid carcinoma: a retrospective clinicopathologic study. Am J Otolaryngol. 2013;34(4):292–5.CrossRefPubMed
57.
go back to reference Podnos YD, Smith D, Wagman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg. 2005;71(9):731–4.PubMed Podnos YD, Smith D, Wagman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg. 2005;71(9):731–4.PubMed
58.
go back to reference Smith VA, Sessions RB, Lentsch EJ. Cervical lymph node metastasis and papillary thyroid carcinoma: does the compartment involved affect survival? Experience from the SEER database. J Surg Oncol. 2012;106(4):357–62.CrossRefPubMed Smith VA, Sessions RB, Lentsch EJ. Cervical lymph node metastasis and papillary thyroid carcinoma: does the compartment involved affect survival? Experience from the SEER database. J Surg Oncol. 2012;106(4):357–62.CrossRefPubMed
59.
go back to reference Kim KM, Park JB, Bae KS, Kim CB, Kang DR, Kang SJ. Clinical prognostic index for recurrence of papillary thyroid carcinoma including intraoperative findings. Endocr J. 2013;60(3):291–7.CrossRefPubMed Kim KM, Park JB, Bae KS, Kim CB, Kang DR, Kang SJ. Clinical prognostic index for recurrence of papillary thyroid carcinoma including intraoperative findings. Endocr J. 2013;60(3):291–7.CrossRefPubMed
60.
go back to reference Carty SE, Cooper DS, Doherty GM, Duh QY, Kloos RT, Mandel SJ, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid. 2009;19(11):1153–8.CrossRefPubMed Carty SE, Cooper DS, Doherty GM, Duh QY, Kloos RT, Mandel SJ, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid. 2009;19(11):1153–8.CrossRefPubMed
61.
go back to reference Stack BC, Ferris RL, Goldenberg D, Haymart M, Shaha A, Sheth S, et al. American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer. Thyroid. 2012;22(5):501–8.CrossRefPubMed Stack BC, Ferris RL, Goldenberg D, Haymart M, Shaha A, Sheth S, et al. American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer. Thyroid. 2012;22(5):501–8.CrossRefPubMed
62.
go back to reference Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. 1995. Radiat Res. 2012;178(2):AV43–60.CrossRefPubMed Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. 1995. Radiat Res. 2012;178(2):AV43–60.CrossRefPubMed
63.
go back to reference Conzo G, Docimo G, Pasquali D, Mauriello C, Gambardella C, Esposito D, Tartaglia E, et al. Predictive value of nodal metastases on local recurrence in the management of differentiated thyroid cancer. Retrospective clinical study. BMC Surg. 2013;13 Suppl 2:S3.CrossRefPubMedPubMedCentral Conzo G, Docimo G, Pasquali D, Mauriello C, Gambardella C, Esposito D, Tartaglia E, et al. Predictive value of nodal metastases on local recurrence in the management of differentiated thyroid cancer. Retrospective clinical study. BMC Surg. 2013;13 Suppl 2:S3.CrossRefPubMedPubMedCentral
64.
go back to reference Kim KE, Kim EK, Yoon JH, Han KH, Moon HJ, Kwak JY. Preoperative prediction of central lymph node metastasis in thyroid papillary microcarcinoma using clinicopathologic and sonographic features. World J Surg. 2013;37(2):385–91.CrossRefPubMed Kim KE, Kim EK, Yoon JH, Han KH, Moon HJ, Kwak JY. Preoperative prediction of central lymph node metastasis in thyroid papillary microcarcinoma using clinicopathologic and sonographic features. World J Surg. 2013;37(2):385–91.CrossRefPubMed
65.
go back to reference Calò PG, Medas F, Pisano G, Boi F, Baghino G, Mariotti S, Nicolosi A. Differentiated thyroid cancer: indications and extent of central neck dissection: our experience. Int J Surg Oncol. 2013;2013:625193.PubMedPubMedCentral Calò PG, Medas F, Pisano G, Boi F, Baghino G, Mariotti S, Nicolosi A. Differentiated thyroid cancer: indications and extent of central neck dissection: our experience. Int J Surg Oncol. 2013;2013:625193.PubMedPubMedCentral
66.
go back to reference Conzo G, Docimo G, Mauriello C, Gambardella C, Esposito D, Cavallo F, Tartaglia E, et al. The current status of lymph node dissection in the treatment of papillary thyroid cancer. A literature review. Clin Ter. 2013;164(4):e343–6.PubMed Conzo G, Docimo G, Mauriello C, Gambardella C, Esposito D, Cavallo F, Tartaglia E, et al. The current status of lymph node dissection in the treatment of papillary thyroid cancer. A literature review. Clin Ter. 2013;164(4):e343–6.PubMed
67.
go back to reference White ML, Gauger PG, Doherty GM. Central lymph node dissection in differentiated thyroid cancer. World J Surg. 2007;31(5):895–904.CrossRefPubMed White ML, Gauger PG, Doherty GM. Central lymph node dissection in differentiated thyroid cancer. World J Surg. 2007;31(5):895–904.CrossRefPubMed
68.
go back to reference Bonnet S, Hartl D, Leboulleux S, Baudin E, Lumbroso JD, Al Ghuzlan A, et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endrocrinol Metab. 2009;94(4):1162–7.CrossRef Bonnet S, Hartl D, Leboulleux S, Baudin E, Lumbroso JD, Al Ghuzlan A, et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endrocrinol Metab. 2009;94(4):1162–7.CrossRef
69.
go back to reference Caliskan M, Park JH, Jeong JS, Lee CR, Park SK, Kang SW, et al. Role of prophylactic ipsilateral central compartment lymph node dissection in papillary thyroid microcarcinoma. Endocr J. 2012;59(4):305–11.CrossRefPubMed Caliskan M, Park JH, Jeong JS, Lee CR, Park SK, Kang SW, et al. Role of prophylactic ipsilateral central compartment lymph node dissection in papillary thyroid microcarcinoma. Endocr J. 2012;59(4):305–11.CrossRefPubMed
70.
go back to reference Barczyński M, Konturek A, Stopa M, Nowak W. Prophylactic central neck dissection for papillary thyroid cancer. Br J Surg. 2013;100(3):410–8.CrossRefPubMed Barczyński M, Konturek A, Stopa M, Nowak W. Prophylactic central neck dissection for papillary thyroid cancer. Br J Surg. 2013;100(3):410–8.CrossRefPubMed
71.
go back to reference Wang TS, Cheung K, Farrokhyar F, Roman SA, Sosa JA. A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer. Ann Surg Oncol. 2013;20(11):3477–83.CrossRefPubMed Wang TS, Cheung K, Farrokhyar F, Roman SA, Sosa JA. A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer. Ann Surg Oncol. 2013;20(11):3477–83.CrossRefPubMed
72.
go back to reference Chisholm EJ, Kulinskaya E, Tolley NS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope. 2009;119(6):1135–9.CrossRefPubMed Chisholm EJ, Kulinskaya E, Tolley NS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope. 2009;119(6):1135–9.CrossRefPubMed
73.
go back to reference Calò PG, Pisano G, Medas F, Marcialis J, Gordini L, Erdas E, Nicolosi A. Total thyroidectomy without prophylactic central neck dissection in clinically node-negative papillary thyroid cancer: is it an adequate treatment? World J Surg Oncol. 2014;20(12):152.CrossRef Calò PG, Pisano G, Medas F, Marcialis J, Gordini L, Erdas E, Nicolosi A. Total thyroidectomy without prophylactic central neck dissection in clinically node-negative papillary thyroid cancer: is it an adequate treatment? World J Surg Oncol. 2014;20(12):152.CrossRef
74.
go back to reference Raffaelli M, De Crea C, Sessa L, Fadda G, Bellantone C, Lombardi CP. Ipsilateral central neck dissection plus frozen section examination versus prophylactic bilateral central neck dissection in cN0 papillary thyroid carcinoma. Ann Surg Oncol. 2015;22(7):2302–8.CrossRefPubMed Raffaelli M, De Crea C, Sessa L, Fadda G, Bellantone C, Lombardi CP. Ipsilateral central neck dissection plus frozen section examination versus prophylactic bilateral central neck dissection in cN0 papillary thyroid carcinoma. Ann Surg Oncol. 2015;22(7):2302–8.CrossRefPubMed
75.
go back to reference Carling T, Carty SE, Ciarleglio MM, Cooper DS, Doherty GM, Kim LT, et al. American Thyroid Association Surgical Affairs Committee: American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid. 2012;22(3):237–44.CrossRefPubMed Carling T, Carty SE, Ciarleglio MM, Cooper DS, Doherty GM, Kim LT, et al. American Thyroid Association Surgical Affairs Committee: American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid. 2012;22(3):237–44.CrossRefPubMed
76.
go back to reference Takami H, Ito Y, Okamoto T, Onoda N, Noguchi H, Yoshida A. Revisiting the guidelines issued by the Japanese Society of Thyroid Surgeons and Japan Association of Endocrine Surgeons: a gradual move towards consensus between Japanese and western practice in the management of thyroid carcinoma. World J Surg. 2014;38(8):2002–10.CrossRefPubMed Takami H, Ito Y, Okamoto T, Onoda N, Noguchi H, Yoshida A. Revisiting the guidelines issued by the Japanese Society of Thyroid Surgeons and Japan Association of Endocrine Surgeons: a gradual move towards consensus between Japanese and western practice in the management of thyroid carcinoma. World J Surg. 2014;38(8):2002–10.CrossRefPubMed
77.
go back to reference Sancho JJ, Lennard TW, Paunovic I, Triponez F, Sitges-Serra A. Prophylactic central neck dissection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg. 2014;399(2):155–63.CrossRefPubMed Sancho JJ, Lennard TW, Paunovic I, Triponez F, Sitges-Serra A. Prophylactic central neck dissection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg. 2014;399(2):155–63.CrossRefPubMed
78.
go back to reference Roh JL, Park JY, Park CI. Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients. Pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg. 2007;245(4):604–10.CrossRefPubMedPubMedCentral Roh JL, Park JY, Park CI. Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients. Pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg. 2007;245(4):604–10.CrossRefPubMedPubMedCentral
79.
go back to reference Gyorki DE, Untch B. Prophylactic central neck dissection in differentiated thyroid cancer: an assessment of the evidence. Ann Surg Oncol. 2013;20(7):2285–9.CrossRefPubMed Gyorki DE, Untch B. Prophylactic central neck dissection in differentiated thyroid cancer: an assessment of the evidence. Ann Surg Oncol. 2013;20(7):2285–9.CrossRefPubMed
80.
go back to reference Chen R, Wei T, Li ZH, Gong RX, Zhu JQ. Predictors of level V lymphatic metastasis in papillary thyroid carcinoma. Zhonghua Wai Ke Za Zhi. 2012;50(7):625–8.PubMed Chen R, Wei T, Li ZH, Gong RX, Zhu JQ. Predictors of level V lymphatic metastasis in papillary thyroid carcinoma. Zhonghua Wai Ke Za Zhi. 2012;50(7):625–8.PubMed
Metadata
Title
Role of prophylactic central compartment lymph node dissection in clinically N0 differentiated thyroid cancer patients: analysis of risk factors and review of modern trends
Authors
Giovanni Conzo
Ernesto Tartaglia
Nicola Avenia
Pier Giorgio Calò
Annamaria de Bellis
Katherine Esposito
Claudio Gambardella
Sergio Iorio
Daniela Pasquali
Luigi Santini
Maria Antonia Sinisi
Antonio Agostino Sinisi
Mario Testini
Andrea Polistena
Giuseppe Bellastella
Publication date
01-12-2016
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2016
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-016-0879-4

Other articles of this Issue 1/2016

World Journal of Surgical Oncology 1/2016 Go to the issue